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Abstract
Background: Patterns of healthcare utilization and costs in patients beginning pharmacotherapy for generalized
anxiety disorder (GAD) have not been well characterized.
Methods: Using a large US health insurance database, we identified all patients with evidence of GAD (ICD-9-CM
diagnosis code 300.02) who initiated pharmacotherapy with medications commonly used to treat GAD (eg,
selective serotonin reuptake inhibitors [SSRIs], venlafaxine, benzodiazepines) between 1/1/2003 and 12/31/2007. We
examined healthcare utilization and costs over the 12-month periods preceding and following date of initial
receipt of such therapy ("pretreatment” and “follow-up”, respectively). Patients with incomplete data were excluded.
Results: A total of 10,275 patients met all study inclusion criteria. Forty-eight percent of patients received SSRIs;
34%, benzodiazepines; and 6%, venlafaxine. SSRIs and venlafaxine were about three times more likely to be used
on a long-term basis (> 90 days) than benzodiazepines (p < 0.01). In general, levels of healthcare utilization were
higher during follow-up than pretreatment. Mean (SD) total healthcare costs increased from $4812 ($10,006) during
pretreatment to $7182 ($22,041) during follow-up (p < 0.01); costs of GAD-related pharmacotherapy during follow-
up were $420 ($485).
Conclusions: More than one-half of patients initiating pharmacotherapy for GAD receive either SSRIs or
venlafaxine. Levels of healthcare utilization and costs are greater in the year following initiation of therapy than in
the immediately preceding one.
Background
Generalized anxiety disorder (GAD) is a chronic condition
characterized by persistent worry or anxiety [1]; it is often
difficult to diagnose because of the wide variety of clinical
presentations and the common occurrence of comorbid
somatic diseases and/or mental disorders. Lifetime preva-
lence of GAD has been estimated to range from 4% to 6%
[2]; annual prevalence has been reported to be about 2%
[3,4]. GAD is two to three times more common in women
than men [3]. GAD is the most common anxiety disorder
among patients presenting to primary care physicians
[5,6], and it is overrepresented in primary care settings,
with point prevalence rates at least 2-3 times higher than
those reported in the community [6,7]. GAD typically
follows a relapsing/remitting pattern; approximately one-
third of patients who achieve remission experience a full
relapse within three years [8].
Recent clinical guidelines recommend first-line treat-
ment with antidepressants–specifically, escitalopram,
paroxetine, or sertraline (all selective serotonin re-
uptake inhibitors [SSRI]), or venlafaxine (a serotonin-
norepinephrine re-uptake inhibitor [SNRI])–on the basis
of their efficacy, safety, and tolerability [9,10]. While
benzodiazepines were the mainstay of GAD treatment
for many years because of their favorable tolerability
and the rapid symptomatic relief that they typically pro-
vide, there is general agreement today that–excepting
patients who are refractory to other available therapies–
they should not be used for more than a few weeks, due
to risks of dependency and sedation, increased risk of
industrial and motor vehicle accidents, and neonatal and
infant mortality when used in late pregnancy or during
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patients receiving benzodiazepines also develop rebound
anxiety, an intensification of previous symptoms, or
withdrawal when treatment is discontinued [13-15]. On
the other hand, antidepressants also are effective in
treating comorbid depression that is common in
patients with GAD, and there is evidence that they may
be more effective than benzodiazepine anxiolytics on the
psychic symptoms of anxiety.
Utilization of pharmacotherapy for GAD in real-world
clinical practice has not been extensively studied. A recent
study based on health insurance claims reported that total
healthcare expenditures increased by $1340 between the
12-month periods before and after a diagnosis of GAD
was first rendered [16]. The few available other studies
have been limited by narrow geographical focus, failure to
distinguish patients with GAD from those with other anxi-
ety disorders, and–in some cases–relatively small numbers
of patients [17-19]. In this study, we investigate patterns of
initial pharmacotherapy for GAD in a large, geographically
diverse population, and changes in healthcare utilization
and costs in the periods immediately before and after
initiation of such therapy.
Methods
Data Source
Data were obtained from the PharMetrics Patient-Centric
Database. The database is comprised of facility, profes-
sional-service, and retail (i.e., outpatient) pharmacy
claims from over 85 health plans. The plans provide
healthcare coverage to approximately 14 million persons
annually throughout the US (Midwest, 35%; Northeast,
21%; South, 31%; West, 13%). All patient identifiers in
the database have been fully encrypted, and the database
is fully compliant with the Health Insurance Portability
and Accountability Act of 1996 (HIPAA).
Information available for each facility and professional-
service claim includes date and place of service, diagnoses
(in ICD-9-CM format), procedures (in ICD-9-CM
[selected plans only] and HCPCS formats), provider speci-
alty, and charged and paid amounts. Data available for
each retail pharmacy claim include the drug dispensed (in
NDC format), the dispensing date, and the quantity dis-
pensed and number of days of therapy supplied (selected
plans only). All claims include a charged amount; the data-
base also provides paid (i.e., reimbursed, including patient
deductible, copayment, and/or coinsurance) amounts.
Selected demographic and eligibility information is also
available, including age, gender, geographic region, cover-
age type, and the dates of insurance coverage. All patient-
level data can be arrayed in chronologic order to provide
a detailed, longitudinal profile of all medical and phar-
macy services used by each plan member. The database
for this study encompassed the period, January 1, 2003
through December 31, 2007 ("study period”).
Study Sample
The source population for our study consisted of all per-
sons with two or more outpatient claims on different
days (during the study period) with a diagnosis of GAD
(ICD-9-CM diagnosis code 300.02). Among these
patients, we identified those initiating pharmacotherapy
with any of a number of medications that are often used
to treat GAD (“GAD-related medications”), as follows:
(1) SSRIs (escitalopram, paroxetine, sertraline); (2) venla-
faxine (an SNRI); (3) benzodiazepines (alprazolam, chlor-
diazepoxide, clonazepam, clorazepate, diazepam,
lorazepam, oxazepam); and (4) other agents (imipramine,
buspirone, hydroxyzine, trifluoperazine) [9,19]. While
fluoxetine, an SSRI, is sometimes used to treat GAD, we
did not include it because it is not indicated for the treat-
ment of GAD, and because there is little or no evidence
from clinical trials supporting its use in this indication.
Date of initial receipt of a GAD-related medication was
designated the “index date”.
Patients without at least one claim with a diagnosis code
of GAD in the 90-day period immediately preceding (and
including) their index date were excluded from the study
sample, as were: (1) patients with less than 12 months of
complete data prior to their index date (“pretreatment”);
(2) patients with less than 12 months of complete data
subsequent to their index date (“follow-up”); (3) patients
with evidence of receipt during the pretreatment period of
any medications commonly used to treat GAD (as noted
above) or any other medication from any such class; (4)
Medicaid beneficiaries; or (5) patients aged ≥ 65 years who
were enrolled in a Medicare supplemental or fee-for-
service plan (their claims histories may be incomplete).
For all remaining patients, we compiled all pharmacy, pro-
fessional service, and facility claims during both the pre-
treatment and follow-up periods.
Patients were then stratified into treatment groups
based on the agent received on the index date (“initial
therapy”). Patients with evidence of receipt of more than
one GAD-related agent on their index date (e.g., SSRI
and a benzodiazepine) were assigned to a “combination
therapy” group.
Measures and Analyses
Baseline demographic and clinical characteristics of
study subjects, including prevalence of selected comor-
bidities (Additional File 1), were characterized on the
basis of information during the 12-month pretreatment
period.
Use of GAD-related medication was examined in
terms of the numbers of patients receiving various
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numbers of pharmacy claims for–and associated ther-
apy-days with–each medication.
Duration of receipt of initial therapy was defined based
on time between the index date and the date of final
receipt of such therapy, where the latter was designated
based on the first pharmacy claim that was followed by a
≥ 28-day “gap” between the final therapy-day associated
with that claim and the date of the next claim (if any) for
such therapy. Thus, for example, if a patient’sd a t eo f
initial receipt of an SSRI was January 1 and 28 days of
such therapy were dispensed, the last day of treatment
was assumed to have been January 28 unless there was
another pharmacy claim for the same agent on or before
February 26 (i.e., 28 days subsequent to January 28). If
the patient had another claim for the same SSRI within
this timeframe, a similar rule was applied to the next
pharmacy claim, and so on.
We examined healthcare utilization during the pre-
treatment and follow-up periods in terms of the numbers
of physician office visits, other outpatient office visits,
emergency department (ED) visits, and hospitalizations.
Length of stay (LOS) also was examined for patients
admitted to hospital. Total healthcare costs were tallied
in terms of: (1) GAD-related medications (initial therapy
as well as all other such agents received during follow-
up); (2) all other pharmacotherapy; (3) physician office
visits; (4) other outpatient visits; (5) ED visits; (6) inpati-
ent care; and (7) all other care. Reimbursed amounts
(including any patient liability, such as co-pays and co-
insurance) were used in all analyses of health-care costs.
Healthcare utilization and costs were characterized on an
overall basis and by month during the pretreatment and
follow-up periods, respectively.
The statistical significance of differences between pre-
treatment and follow-up was assessed using paired t-tests
for continuous variables with approximately normal dis-
tributions, and Wilcoxon signed-rank tests otherwise.
McNemar and Bowker’s tests were used to assess the sta-
tistical significance of differences in categorical variables,
as appropriate. All tests of statistical significance were
two-tailed with an alpha level of 0.05. All analyses were
conducted using SAS
® Proprietary Software, Release 9.1
(SAS Institute Inc., Cary, NC).
Results
We identified 10,275 patients with GAD who initiated
treatment with one of the agents of interest and who also
met all other study entry criteria (Table 1). Mean age
was 37.7 years, and 60% of study subjects were women
(Table 2). Thirty-eight percent of study subjects received
diagnoses of depressive disorders during pretreatment, and
18% had diagnoses of other anxiety disorders.
S S R I sw e r et h em o s tw i d e l yu s e da g e n t s( 4 7 . 6 %o f
study subjects received an SSRI on their index date), fol-
lowed by the benzodiazepines (34.0%), and venlafaxine
(6.3%); 6.6% of patients received combination therapy
on the index date. Among SSRIs, the most commonly
used agents were escitalopram (20.1% of study subjects)
and sertraline (17.5%). Among benzodiazepines, the
most commonly used agents were alprazolam (17.2%)
and lorazepam (7.4%).
Patterns of pharmacotherapy differed substantially by
type of agent received. Patients who initiated therapy
with an SSRI received an average (SD) of 5.9 (4.0) pre-
scriptions; corresponding values for venlafaxine, benzo-
diazepines, and other GAD-related medications were 5.8
(4.3), 3.5 (3.6), and 2.6 (2.7), respectively. Patients who
received combination therapy on the index date had an
average of 9.9 (6.6) prescriptions over 12 months. Mean
(SD) duration of therapy was 24.6 (32.5) days among
patients initiating therapy with benzodiazepines; corre-
sponding figures for venlafaxine, SSRIs, and other GAD-
related medications were 75.5 (64.8) days, 70.4 (59.8)
days, and 32.0 (34.8) days, respectively. Among those
receiving a combination regimen on their index date,
mean duration was 78.0 (60.2) days.
SSRIs and venlafaxine were more likely than benzodia-
zepines to be used on a long-term basis (> 90 days)
(Figure 1). At one year, 41.7% and 43.4% of SSRI and
venlafaxine patients were still receiving treatment; the
corresponding value for benzodiazepine patients was
13.2%.
In general, levels of healthcare utilization were higher
during follow-up than pretreatment. Of particular note,
there was an increase in the number of physician office
visits, from a mean (SD) of 12.6 (13.2) during pretreat-
ment to 16.3 (15.5) during follow-up (Table 3). Mean
total healthcare costs increased by $2370 between pre-
treatment and follow-up (p < 0.01) (Table 4). Costs of
GAD-related pharmacotherapy were $420 ($485) during
follow-up. Costs were highest around the time of ther-
apy initiation (Figure 2).
Discussion
About one-half of all patients beginning a new course of
pharmacotherapy for GAD receive either an SSRI or
venlafaxine. The typical duration of therapy with these
agents was only about three months; almost one-half of
patients who began treatment with an SSRI or venlafax-
ine, however, had evidence of continuing receipt of
medication at one year. Benzodiazepines, which about
one-third of study subjects received as initial therapy,
were administered–not unexpectedly–f o ras h o r t e rp e r -
iod time, and mean duration of therapy was about one
month.
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benzodiazepine had evidence of continuing receipt
beyond 90 days. Lacking information on disease severity,
we could not assess the appropriateness of such long-
term use. To the extent these patients had symptoms
refractory to other medications, long-term treatment
with benzodiazepines may have been appropriate, not-
withstanding well-known risks associated with such ther-
apy (e.g., dependence, cognitive impairment, increased
risk of falls, risk of rebound anxiety) when treatment is
discontinued [11-15]).
Mean total healthcare costs were $2370 higher during
the one-year period of follow-up than in the one-year per-
iod preceding treatment. While we do not know the exact
r e a s o n ( s )f o rt h i sd i f f e r e n c e ,w es u s p e c tt h a ti tm a yb e
related to GAD-related care (GAD-related pharmacother-
apy comprised 18% of this increase), exacerbation of pre-
existing comorbidities or decreased ability to cope with
these conditions, and/or new somatic manifestations of
GAD (e.g., chest pain, gastrointestinal disorders). Further
research is needed to better understand this phenomenon.
The increase in costs (follow-up vs pretreatment) that
we observed is substantially greater than that reported
by Francois and colleagues ($1340). We suspect that the
principal reason for this difference is that our study only
included patients initiating pharmacotherapy for GAD,
while only 44% of the patients in the Francois study
received an antidepressant or anxiolytic anytime during
follow-up [16]. Presumably, patients initiating pharma-
cotherapy for GAD will have more severe illness–and
incur greater costs–than patients newlyd i a g n o s e dw i t h
GAD who do not receive drug therapy.
An important limitation of our study was the omission
of fluoxetine from the group of SSRIs. We excluded
fluoxetine because it is not indicated for the treatment of
GAD, and has not been studied extensively in this
indication. Nonetheless, there is evidence that it may be
prescribed for this disorder [20-23]. In one recent study
of 305 patients with GAD and 232 with social phobia, it
was reported to be the most commonly prescribed SSRI
[18] (benzodiazepines were the most commonly used
medications in both indications). Our exclusion of fluox-
etine undoubtedly resulted in our underestimating the
number of GAD patients beginning therapy with an
SSRI. We note, however, that although fluoxetine was
not on our list of designated GAD-related medications,
patients who received it during the one-year pretreat-
ment period were excluded from our study sample (as
were those who received any other SSRI, any SNRI, or
any benzodiazepine during pretreatment). Thus, patients
could not have been included in our study population if
they were adding a second agent (e.g., a benzodiazepine)
to fluoxetine or switching from fluoxetine to another
agent.
There are several other important limitations of our
study. First, as with all claims database studies, there
may be errors of omission and commission in coding.
Accordingly, some patients with GAD may not have
been included in our study sample due to absence of
appropriate diagnoses on healthcare claims, while others
who received a diagnosis of GAD incorrectly and there-
fore should have been excluded were not. As patient
medical records were not available to us, the degree to
which patients were actually misclassified is unknown.
Also, the database does not contain important clinical
information on disease severity. Without such informa-
tion, it is difficult to assess the appropriateness of the
therapeutic patterns that we observed.
Conclusions
In conclusion, about one-half of all patients beginning a
new course of pharmacotherapy for GAD receive either
Table 1 Selection of study subjects
Patients
Number of patients with ≥ 2 outpatient claims for GAD and 285,820
≥ 1 claims for pharmacotherapy used to treat GAD and 167,538
≥ 1 claims with GAD diagnosis on index date or during 90-day period immediately prior and 55,791
≥ 12 months enrollment prior to index date* and 22,678
≥ 12 months enrollment following index date* and 14,407
No evidence of receipt of any benzodiazepine, SSRI or SNRI in the year prior to index date and** 11,202
No Medicaid insurance and 11,111
Aged < 65 years or 10,398
Aged ≥ 65 years and not enrolled in Medicare supplemental or capitated plans 119
Total of above and 10,517
No missing information on therapy-days on prescription for index drug 10,275
*First-noted claim for medication of interest during study period
**Including agents that are and are not recommended for use in GAD
GAD: generalized anxiety disorder; SSRI: Selective serotonin reuptake inhibitor; SNRI: Serotonin-norepinephrine reuptake inhibitor
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Page 4 of 9Table 2 Demographic and clinical characteristics of study subjects (N = 10,275)*
Characteristic
Age, years
<1 8 1,114 (10.8)
18-44 5,506 (53.6)
45-54 2,176 (21.2)
55-64 1,363 (13.3)
≥ 65 116 (1.1)
Mean (SD) 37.7 (14.9)
Female 6,155 (59.9)
Comorbidities
Mental disorders
Other anxiety disorders 1,813 (17.6)
Depressive disorders 3,885 (37.8)
Bipolar disorder 63 (0.6)
Tension headache 114 (1.1)
Personality disorders 101 (1.0)
Alcohol abuse/alcoholism 19 (0.2)
Drug abuse 132 (1.3)
Suicide attempts 97 (0.9)
Sleep disorders 1,134 (11.0)
Neoplasms 252 (2.5)
Diabetes 396 (3.9)
Migraine 414 (4.0)
Ischemic heart disease 280 (2.7)
Cerebrovascular disease 138 (1.3)
Asthma 664 (6.5)
Painful neuropathic disorders 964 (9.4)
Symptoms, signs, and ill- defined conditions
Fatigue 1,690 (16.4)
Headache 974 (9.5)
Chest pain 1,431 (13.9)
Abdominal pain 1,552 (15.1)
Anxiety- related symptoms 1,627 (15.8)
Any symptoms, signs, and ill- defined conditions 4,692 (45.7)
Pretreatment healthcare costs, $
Mean (SD) 4,812 (10,006)
Median (IQR) 2,118 (896,4,975)
Region
Northeast 3,165 (30.8)
South 1,621 (15.8)
West 1,858 (18.1)
Midwest 3,631 (35.3)
Payer type
HMO 2,971 (28.9)
PPO 4,733 (46.1)
Indemnity 554 (5.4)
Other 283 (2.8)
*Unless otherwise indicated, all values are number (%)
GAD: Generalized anxiety disorder; SAD: Social anxiety disorder; HMO: Health maintenance organization; IQR: Interquartile range; PPO: Preferred provider
organization; SD: Standard deviation
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Page 5 of 9Figure 1 Discontinuation of initial therapy for GAD. GAD: Generalized anxiety disorder; SNRI: Serotonin-norepinephrine reuptake inhibitor;
SSRI: Selective serotonin reuptake inhibitor.
Table 3 Use of healthcare services during pretreatment and follow-up
Pretreatment Follow-Up P-Value
Office visits
Psychiatrists
Mean (SD) 1.0 (3.3) 2.1 (5.1) < 0.01
Median (IQR) 0 (0, 0) 0 (0, 2)
Internists
Mean (SD) 0.9 (2.3) 1.1 (2.9) 0.01
Median (IQR) 0 (0, 1) 0 (0, 1)
General practitioners
Mean (SD) 1.9 (3.3) 2.4 (3.7) < 0.01
Median (IQR) 1 (0, 3) 1 (0, 4)
Other
Mean (SD) 9.1 (12.1) 11.1 (14.2) < 0.01
Median (IQR) 5 (2, 12) 6 (2, 15)
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Page 6 of 9Table 3 Use of healthcare services during pretreatment and follow-up (Continued)
Total
Mean (SD) 12.6 (13.2) 16.3 (15.5) < 0.01
Median (IQR) 8 (4, 16) 11 (6, 21)
Other outpatient office visits
Mean (SD) 1.3 (2.6) 1.5 (3.5) 0.01
Median (IQR) 0 (0, 2) 0 (0, 2)
Total outpatient office visits
Mean (SD) 13.5 (13.6) 17.3 (16.0) < 0.01
Median (IQR) 9 (5, 17) 12 (6, 23)
ED visits
Mean (SD) 0.3 (1.1) 0.3 (1.1) 0.28
Median (IQR) 0 (0, 0) 0 (0, 0)
Hospitalizations
Mean (SD) 0.3 (2.0) 0.4 (2.4) 0.04
Median (IQR) 0 (0, 0) 0 (0, 0)
GAD: Generalized anxiety disorder; SD: Standard deviation; ED: Emergency department; IQR: Interquartile range
Table 4 Mean healthcare costs during pretreatment and follow-up
Pretreatment Follow-Up P-Value
Pharmacotherapy
GAD related
SSRIs 0 (0) 302 (385)
SNRIs 0 (0) 82 (331)
Benzodiazepines 0 (0) 28 (119)
Other 0 (0) 8 (55)
Total of above 0 (0) 420 (485)
All other 639 (1,416) 1,128 (2,463) < 0.01
Total of above 639 (1,416) 1,548 (2,552) < 0.01
Outpatient care
Physician’s office visits
Psychiatrists 117 (434) 220 (660) < 0.01
Internists 90 (282) 117 (508) 0.03
General practitioners 170 (387) 217 (432) < 0.01
All other 1,135 (1,916) 1,444 (2,559) < 0.01
Total of above 1,511 (2,110) 1,997 (2,863) < 0.01
Other outpatient office vists 747 (2,527) 1,101 (5,021) < 0.01
Total of above 2,258 (3,628) 3,098 (6,357) < 0.01
ED 236 (900) 279 (1,152) 0.20
Inpatient care 1,173 (7,433) 1,573 (17,214) 0.05
All other 506 (1,913) 684 (3,514) < 0.01
Total 4,812 (10,006) 7,182 (22,041) < 0.01
*All values are mean $ (SD)
GAD: Generalized anxiety disorder; SSRI: Selective serotonin reuptake inhibitor; SNRI: Serotonin-norepinephrine reuptake inhibitor; ED: Emergency department; SD:
Standard deviation
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Page 7 of 9an SSRI or venlafaxine, and roughly one-third receive a
benzodiazepine. Levels of healthcare utilization and
costs are greater in the year following initiation of ther-
apy than in the immediately preceding one.
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